Managing oncology agents: an HMO's perspective.
The only way to accomplish the goals discussed is for health plans to collaborate more constructively with the oncologist community. We have reached out to providers, but there is still plenty of room for improvement. It is critical for both our success and that of the oncology community, because no one benefits from an adversarial relationship. We have not really sat down as partners with care providers to talk about what both parties see as emerging issues and how to best address them. We are at a point in oncology where we have this opportunity.
Jaramillo
Robert
R
Altius Health Plans, South Jordan, Utah, USA.
D000970:Antineoplastic Agents / Q000191:economics*; D003299:Cooperative Behavior; D003363:Cost Control / Q000458:organization & administration; D003362:Cost-Benefit Analysis; D006279:Health Maintenance Organizations; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics; D011785:Quality Assurance, Health Care; D014481:United States
D000970:Antineoplastic Agents